Full-Time
Senior IT Project Manager
Curaleaf
1,001-5,000 employees
Cannabis cultivation, processing, and retailing
Compensation Overview
$145k - $161k/yr
No H1B Sponsorship
Stamford, CT, USA
In Person
Bachelor's
 IT Operations (1) |
|---|
Get referred to Curaleaf
See people who can refer or advise you
- A bachelor's degree in Computer Science, IT, Business, or a related field.
- At least 7 years of IT project management experience with large, distributed teams.
- PMI-PMP, Certified ScrumMaster, or equivalent certification.
- Expert knowledge of project methodologies and frameworks, including PMBOK, Waterfall, Agile, and Scrum.
- Experience leading projects within digital transformation initiatives or significant organizational change programs.
- Experience with the Azure DevOps suite or an equivalent tool set.
- Proficiency with ServiceNow SPM/CWM, Microsoft Project, Microsoft Project Web App, and Office 365.
- A proficient understanding of the software development life cycle with a focus on agility, quality, and security.
- Demonstrated ability to manage project scope, timeline, and budget.
- Experience managing vendor relationships, statements of work, and third-party delivery teams.
- Drive key components of the organization's digital transformation program, ensuring alignment with strategic business and technology objectives.
- Lead multiple concurrent IT projects from initiation through completion.
- Develop and manage comprehensive project plans, including scope, schedule, budget, risks, and quality.
- Apply appropriate methodologies, including Waterfall, Agile, and Scrum, based on project requirements.
- Facilitate key project meetings and steering committee updates, managing cross-functional stakeholder relationships across IT, the business, and external partners.
- Prepare and deliver executive and steering committee reporting, including RAG status, milestone tracking, and risk visibility.
- Manage project budgets and resource allocation to ensure optimal utilization.
- Monitor project progress and report on milestones and deliverables.
- Resolve team impediments and collaborate with other Project Managers and Scrum Masters.
- Identify, assess, and mitigate project risks to ensure successful delivery.
- Collaborate with cross-functional teams, stakeholders, and vendors.
- Mentor junior project managers and provide team leadership.
- Experience operating within a regulated industry, such as cannabis, pharmaceutical, healthcare, or CPG, with familiarity managing regulatory, GxP, or multi-state compliance requirements within IT projects.
- Experience with data privacy and security frameworks, such as HIPAA, GDPR, and CCPA, as applied to project delivery.
- Experience operating within a formal PMO governance model with defined phase gates and executive steering committees.
Curaleaf is a cannabis company that grows, processes, and sells cannabis products for medical and recreational use. It offers items such as tinctures, flowers, and edibles, and uses encapsulation technology to improve product absorption and effectiveness. Customers can buy at dispensaries or online, and the company also provides medical consultations and guidance services. Differentiators include its vertically integrated model (cultivation, processing, and retail) and its social responsibility efforts, such as the B NOBLE program that supports individuals with cannabis-related non-violent charges. The company’s goal is to provide reliable cannabis products and related services to a wide range of customers while advancing responsible access and advocacy through programs like B NOBLE.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wakefield, Massachusetts
Founded
2010
Get referred to Curaleaf
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $340 million, up 10%, with $12 million net income.
- International revenue rose 26% to $51 million, driven by Germany, the U.K., and Poland.
- Florida openings in July 2026 and September 2026 keep same-state retail momentum strong.
What critics are saying
- Aurora's September 2026 rejection frames Curaleaf's hostile bid as debt-driven desperation.
- Curaleaf carried $611.5 million debt and only $107 million cash on June 30, 2026.
- A failed Aurora deal leaves Curaleaf exposed to slower U.S. growth and refinancing pressure.
What makes Curaleaf unique
- Curaleaf built a 167-store footprint by September 2026, with 76 Florida locations.
- Its July 2026 Spain AEMPS registration made Curaleaf first for standardized cannabis preparations.
- Germany's Four 20 Pharma ownership gives Curaleaf EU-GMP production and distribution leverage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Life Insurance
Disability Insurance
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Curaleaf Holdings has opened a new cannabis dispensary in downtown Boston at 21 Milk St., near Downtown Crossing. The location opened on 4 September, offering patients expanded retail space and a broader selection of products. The dispensary will stock Curaleaf's portfolio of cannabis brands, including Dark Heart, Select, FIND, Anthem and Grassroots. Knowledgeable staff will assist customers in selecting products suited to their needs. A grand opening celebration is scheduled for 8 September, featuring in-store promotions, a Meet the Grower event, and brand activations. The store operates from 09:00 to 20:00 Monday through Saturday, and 09:00 to 18:00 on Sunday. The opening follows the closure of Curaleaf's former Provincetown dispensary.
Curaleaf has formally launched its hostile takeover bid for Aurora Cannabis, offering $4 per share directly to shareholders. The offer represents a 45% premium on Aurora's 30-day average share price from 10 August, before Curaleaf announced its intentions. The proposed deal would create a combined company with a $3 billion market cap. Curaleaf projects approximately $40 million in annual cost synergies from the merger. The acquisition aims to give Curaleaf access to EU medical cannabis export markets, particularly Germany. Aurora possesses EU-GMP cultivation capacity that meets strict German import standards. Federal restrictions make direct cannabis exports challenging for US firms like Curaleaf. Curaleaf CEO Boris Jordan said initial friendly discussions with Aurora CEO Miguel Martin earlier this summer stalled, prompting the direct shareholder approach. Aurora's board has formed a special committee to review the offer.
Curaleaf Holdings reported second quarter 2026 revenue of $340 million, representing 10% year-over-year growth driven by domestic and international segments that grew 7% and 26%, respectively. International revenue reached $51 million. The cannabis company posted net income of $12 million and adjusted EBITDA of $70 million, reflecting a 21% margin. Gross profit margin stood at 50%. Chairman and CEO Boris Jordan said the results demonstrate the company's "Built for Growth" strategy is gaining traction. He noted this marks the second consecutive quarter of domestic year-over-year growth. Curaleaf ended the quarter with $107 million in cash and $611.5 million in outstanding debt. The company invested $32.9 million in capital expenditures during the six-month period, focused on facility upgrades and automation.
Curaleaf Holdings has opened its 75th dispensary in Florida, located in Boynton Beach. The cannabis retailer now operates 167 locations nationwide, with Florida representing nearly half of its retail footprint. The new store at 3575 W. Boynton Beach Boulevard is the company's sixth Florida opening this year. It offers medical cannabis products including Anthem pre-rolls, Dark Heart ultra-premium flower, and Select vaping products. Boris Jordan, chairman and CEO, said the opening reinforces Curaleaf's commitment to expanding access to cannabis products across Florida. A grand opening celebration is scheduled for 31 July and 1 August, featuring special promotions and giveaways. The dispensary operates 9:00 to 20:30 Monday through Saturday, and 10:00 to 18:00 on Sunday.
Curaleaf Holdings has become the first company to secure registration for standardised cannabis preparations in Spain under the country's new regulatory framework, Royal Decree 903/2025. Spain's medicines agency AEMPS approved two preparations — THC-dominant and CBD-dominant — developed by Curaleaf's Spanish manufacturing subsidiary. The registrations enable supply to hospital pharmacies, where the preparations can be used in magistral formulas under medical prescription. Royal Decree 903/2025, approved in October 2025, establishes Spain's regulatory framework for medicinal cannabis, setting production and quality standards. Curaleaf operates an EU-GMP certified manufacturing facility and R&D laboratory in Alicante. The company secured Spain's first licence to process medicinal cannabis derivatives for commercial distribution in May 2020. The preparations are expected to become available to patients through hospital pharmacies as Spain's regulated system develops.